Assess the Immunogenicity, Safety & Reactogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants (6-12 Weeks of Age at First Dose) Previously Uninfected With Human Rotavirus.
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2016
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
- 30 Nov 2006 Status change
- 28 Sep 2006 Status change